Genome-editing specialist Precision BioSciences says Baxalta Inc.'s increasing commitment to, and expertise in, immuno-oncology made it the obvious choice for the Duke University spinout to partner with on developing a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed against multiple cancers.
Baxalta and Precision earlier this month inked a collaboration – worth up to $1.7bn – which will use Precision's ARCUS...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

